Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness
T Gamberi, G Chiappetta, T Fiaschi… - Medicinal Research …, 2022 - Wiley Online Library
Auranofin is an oral gold (I) compound, initially developed for the treatment of rheumatoid
arthritis. Currently, Auranofin is under investigation for oncological application within a drug …
arthritis. Currently, Auranofin is under investigation for oncological application within a drug …
Potential anticancer activity of auranofin
T Onodera, I Momose, M Kawada - Chemical and Pharmaceutical …, 2019 - jstage.jst.go.jp
Gold compounds have a long history of use in medicine. Auranofin was developed more
than 30 years ago as an oral therapy for rheumatoid arthritis. Now, however, auranofin is …
than 30 years ago as an oral therapy for rheumatoid arthritis. Now, however, auranofin is …
The role of the thioredoxin detoxification system in cancer progression and resistance
M Jovanović, A Podolski-Renić, M Krasavin… - Frontiers in Molecular …, 2022 - frontiersin.org
The intracellular redox homeostasis is a dynamic balancing system between the levels of
free radical species and antioxidant enzymes and small molecules at the core of cellular …
free radical species and antioxidant enzymes and small molecules at the core of cellular …
DNAJA1 promotes cancer metastasis through interaction with mutant p53
Accumulation of mutant p53 (mutp53) is crucial for its oncogenic gain of function activity.
DNAJA1, a member of J-domain containing proteins or heat shock protein 40, is shown to …
DNAJA1, a member of J-domain containing proteins or heat shock protein 40, is shown to …
Novel TrxR1 inhibitors show potential for glioma treatment by suppressing the invasion and sensitizing glioma cells to chemotherapy
M Jovanović, M Dragoj, D Zhukovsky… - Frontiers in Molecular …, 2020 - frontiersin.org
Currently, available glioblastoma (GBM) treatment remains ineffective, with relapse after
initial response and low survival rate of GBM patients. The reasons behind limited capacities …
initial response and low survival rate of GBM patients. The reasons behind limited capacities …
Further exploration of DVD-445 as a lead thioredoxin reductase (TrxR) inhibitor for cancer therapy: optimization of potency and evaluation of anticancer potential
M Jovanović, D Zhukovsky, A Podolski-Renić… - European Journal of …, 2020 - Elsevier
A series of analogs of the earlier reported lead compound DVD-445 (thioredoxin reductase
inhibitor with anticancer activity) has been synthesized via a modified Ugi reaction and …
inhibitor with anticancer activity) has been synthesized via a modified Ugi reaction and …
Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new …
M Jovanović, D Zhukovsky, A Podolski-Renić… - European Journal of …, 2019 - Elsevier
A series of peptidomimetic compounds incorporating an electrophilic moiety was
synthesized using the Ugi reaction. These compounds (termed the Ugi Michael acceptors or …
synthesized using the Ugi reaction. These compounds (termed the Ugi Michael acceptors or …
Integrated multiomic analysis and high‐throughput screening reveal potential gene targets and synergetic drug combinations for osteosarcoma therapy
W Zhang, L Qi, Z Liu, S He, C Wang, Y Wu, L Han… - MedComm, 2023 - Wiley Online Library
Although great advances have been made over the past decades, therapeutics for
osteosarcoma are quite limited. We performed long‐read RNA sequencing and tandem …
osteosarcoma are quite limited. We performed long‐read RNA sequencing and tandem …
Optimization of the solvent and in vivo administration route of auranofin in a syngeneic non-small cell lung cancer and glioblastoma mouse model
L Freire Boullosa, J Van Loenhout, C Hermans… - Pharmaceutics, 2022 - mdpi.com
The antineoplastic activity of the thioredoxin reductase 1 (TrxR) inhibitor, auranofin (AF), has
already been investigated in various cancer mouse models as a single drug, or in …
already been investigated in various cancer mouse models as a single drug, or in …
[HTML][HTML] 223-Radium for metastatic osteosarcoma: Combination therapy with other agents and external beam radiotherapy
Background Bone-seeking radiopharmaceuticals can deposit radiation selectively to some
osteosarcoma tumours because of the bone-forming nature of this cancer. Objectives This is …
osteosarcoma tumours because of the bone-forming nature of this cancer. Objectives This is …